Login to Your Account



Catching Up to U.S., Europe

China Clarifies Phase IV Study Rules with Proposed Guidelines

By Cornelia Zou
Contributing Writer

Wednesday, November 6, 2013

HONG KONG – Authorities in China are working to plug a regulatory hole related to post-market studies for new chemical entities (NCE) and biological drugs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription